Cel-Sci's Teva Connection May Prove To Be Significant Print E-mail
By Vinny Cassano   
Friday, 01 April 2011 04:28

Shares of Cel-Sci Corp jumped higher by twenty percent during early trading on Wednesday of this week and appear to have broken into a new trend

after the company announced that the Israeli Ministry of Health had approved the initiation of enrollment for the Phase III Multikine trial.  The latest trading in the stock has shares trying to stay above the SMA 200. If prices can break and stay above that 200 day moving average mark, the stock could be headed higher once again.

What is significant about this week's announcement is not that the Israeli medical authorities have given the trial a green light - after all, Cel-Sci has announced the trial-commencement approval of each and every country along the way - but the fact that Teva is going to be conducting the Multikine trial at three locations in Israel makes this approval noteworthy.

Teva Pharmaceuticals Industries is a big player in the global pharmaceutical market and having that name attached to any clinical trial adds a certain amount of validation and credibility to a still-developing company.  Shares of Rexahn, for example, spiked considerably after Teva purchased a few million dollars worth of RNN.

That said, the amount Teva will spend on conducting the Multikine trial in Israel is small beans in the big scheme of things, but big pharma has one thing in common with the small investor - if the risk/reward profile of an investment looks good, then jump on it.

If Multikine makes it to market, or even makes it to late stage Phase III with positive interim results along the way, then CVM will be trading for much higher prices than where the stock sits today.  For Teva, if Multikine ever makes it to market and works as advertised by Cel-Sci, then the rewards are going to be well worth the risk of an investment in this trial.

There have been some concerns expressed by investors about the legitimacy of Cel-Sci, concerns which I believe are unfounded (although the company does defend itself against Internet rumors), but nothing will add validation, legitimacy and credibility like data showing steady enrollment at multiple locations in the world wide trial.

Nearly 900 patients are due to be enrolled in this trial, an ambitious number, yet so far there have been zero enrollments, as far as we know.

Maybe a big player like Teva can get the ball rolling in Israel.

CVM retreated later in the day after an early spike.

Volume was well over four times the daily average.

MCET might be on the move again

Already having experienced a nice early-2011 run, shares of MultiCell technologies have been moving up again on increasing volume and touched prices on Monday that would make MCET a near-double in just over a week's time. The trading action early in the week could be indicative that some news may be close to being released - no news accompanied the previous early-year run - but it's also possible that the move is simply the result of day and momentum trading.

There were a whole new slew of eyes on MCET on Tuesday, when the stock made the Yahoo! Finance home page under the "Bullish" column for 'Community Sentiment.'

Aside from the short term trading aspect of this volatile penny play, MCET also holds some long term potential. The two pipeline candidates far enough along to create buzz are MCT-125, a treatment for fatigue in MS patients (a Phase II product) and the Ideal BioStent, which was recently purchased by Multicell's majority-owned subsidiary Xenogenics.

It's been a while since MultiCell has released significant news, and any relevant company update could have this stock trading up by a very significant percentage; even moreso than the short term double. Keep an eye on MCET.

Disclosure:  Long CVM, MCET

Vinny also authors the popular stock investing blog VFC's Stock House.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter